Multiply resistant gram-positive bacteria: Vancomycin-resistant enterococcus in solid organ transplant recipients

American Journal of Transplantation

Volumn 9, Issue SUPPL. 4, 2009, Pages

  Munoz P ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Colonization; Daptomycin; Linezolid; Quinupristin dalfopristin; Tigecycline; Vancomycin resistant Enterococcus

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CHLORAMPHENICOL; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; FOSFOMYCIN; LINEZOLID; NITROFURANTOIN; ORITAVANCIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ABSCESS DRAINAGE; ARTHRALGIA; BACTEREMIA; BACTERIAL COLONIZATION; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CATHETER INFECTION; CHOLANGIOGRAPHY; CLINICAL TRIAL; DEBRIDEMENT; ENDOCARDITIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTEROCOCCAL INFECTION; EYE TOXICITY; GRAFT RECIPIENT; HUMAN; INFECTION; INTRAVASCULAR INFECTION; LACTIC ACIDOSIS; MYALGIA; NAUSEA; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; T TUBE; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; ORGAN TRANSPLANTATION; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 72949117698     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02893.x     Document Type: Review

References (80)

1. Patel R, Allen SL, Manahan JM et al. Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transpl 2001 7 : 27 31.
2. Reik R, Tenover FC, Klein E, McDonald LC. The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagn Microbiol Infect Dis 2008 62 : 81 85. Epub 2008 May 27.
3. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: Results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006 12 : 844 852.
4. Werner G, Coque TM, Hammerum AM et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008 13 : 19046.
5. Mlynarczyk G, Grzybowska W, Mlynarczyk A et al. Occurrence of glycopeptide-resistant enterococci in transplant medicine internal wards in 2001-2005. Transplant Proc 2007 39 : 2886 2889.
6. Freitas MC, Pacheco-Silva A, Barbosa D et al. Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients. BMC Infect Dis 2006 6 : 133.
7. McNeil SA, Malani PN, Chenoweth CE et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: A prospective surveillance study. Clin Infect Dis 2006 42 : 195 203. Epub 2005 Dec 12.
8. Hagen EA, Lautenbach E, Olthoff K, Blumberg EA. Low prevalence of colonization with vancomycin-resistant Enterococcus in patients awaiting liver transplantation. Am J Transplant 2003 3 : 902 905.
9. Russell DL, Flood A, Zaroda TE et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant 2008 8 : 1737 1743. Epub 2008 Jun 28.
10. Bakir M, Bova JL, Newell KA, Millis JM, Buell JF, Arnow PM. Epidemiology and clinical consequences of vancomycin-resistant enterococci in liver transplant patients. Transplantation 2001 72 : 1032 1037.
11. Newell KA, Millis JM, Arnow PM et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation 1998 65 : 439 442.
12. Nusair A, Jourdan D, Medcalf S et al. Infection control experience in a cooperative care center for transplant patients. Infect Control Hosp Epidemiol 2008 29 : 424 429.
13. Asensio A, Ramos A, Cuervas-Mons V et al. Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl 2008 14 : 799 805.
14. Malani PN, Dyke DB, Pagani FD, Armstrong WS, Chenoweth CE. Successful treatment of vancomycin resistant Enterococcus faecium mediastinitis associated with left ventricular assist devices. Ann Thorac Surg 2003 76 : 1719 1720.
15. Paterson DL, Dominguez EA, Chang FY, Snydman DR, Singh N. Infective endocarditis in solid organ transplant recipients. Clin Infect Dis 1998 26 : 689 694. (Pubitemid 28155022)
16. Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: Cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. South Med J 2003 96 : 818 820.
17. Orloff SL, Busch AM, Olyaei AJ et al. Vancomycin-resistant Enterococcus in liver transplant patients. Am J Surg 1999 177 : 418 422.
18. Bhavnani SM, Drake JA, Forrest A et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000 36 : 145 158.
19. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med 2001 135 : 484 492.
20. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant Enterococcus in a level 1 trauma center. Clin Infect Dis 2002 34 : 922 929. Epub 2002 Mar 4.
21. Ghanem G, Hachem R, Jiang Y, Chemaly RF, Raad I. Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol 2007 28 : 1054 1059. Epub 2007 Jul 12.
22. Donskey CJ, Chowdhry TK, Hecker MT et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000 343 : 1925 1932.
23. Drees M, Snydman DR, Schmid CH et al. Prior environmental contamination increases the risk of acquisition of vancomycin-resistant enterococci. Clin Infect Dis 2008 46 : 678 685.
24. Beltrami EM, Singer DA, Fish L et al. Risk factors for acquisition of vancomycin-resistant enterococci among patients on a renal ward during a community hospital outbreak. Am J Infect Control 2000 28 : 282 285.
25. Ostrowsky BE, Venkataraman L, D'Agata EM, Gold HS, DeGirolami PC, Samore MH. Vancomycin-resistant enterococci in intensive care units: High frequency of stool carriage during a non-outbreak period. Arch Intern Med 1999 159 : 1467 1472.
26. Suntharam N, Lankford MG, Trick WE, Peterson LR, Noskin GA. Risk factors for acquisition of vancomycin-resistant enterococci among hematology-oncology patients. Diagn Microbiol Infect Dis 2002 43 : 183 188.
27. Kritsotakis EI, Christidou A, Roumbelaki M, Tselentis Y, Gikas A. The dynamic relationship between antibiotic use and the incidence of vancomycin-resistant Enterococcus: Time-series modelling of 7-year surveillance data in a tertiary-care hospital. Clin Microbiol Infect 2008 14 : 747 754.
28. MacIntyre CR, Empson M, Boardman C, Sindhusake D, Lokan J, Brown GV. Risk factors for colonization with vancomycin-resistant enterococci in a Melbourne hospital. Infect Control Hosp Epidemiol 2001 22 : 624 629.
29. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: Why are they here, and where do they come from? Lancet Infect Dis 2001 1 : 314 325.
30. Pfundstein J, Roghmann MC, Schwalbe RS et al. A randomized trial of surgical antimicrobial prophylaxis with and without vancomycin in organ transplant patients. Clin Transplant 1999 13 : 245 252.
31. Papanicolaou GA, Meyers BR, Meyers J et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality. Clin Infect Dis 1996 23 : 760 766.
32. Linares L, Cervera C, Cofan F et al. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. Transplant Proc 2007 39 : 2222 2224.
33. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006 42 (Suppl 1 S25 S34.
34. Willems RJ, Top J, van Santen M et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005 11 : 821 828.
35. Ma JZ. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002 51 : 902.
36. Kurup A, Chlebicki MP, Ling ML et al. Control of a hospital-wide vancomycin-resistant Enterococci outbreak. Am J Infect Control 2008 36 : 206 211.
37. Ledeboer NA, Tibbetts RJ, Dunne WM. A new chromogenic agar medium, chromID VRE, to screen for vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. Diagn Microbiol Infect Dis 2007 59 : 477 479. Epub 2007 Sep 21.
38. Ledeboer NA, Das K, Eveland M et al. Evaluation of a novel chromogenic agar medium for isolation and differentiation of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis isolates. J Clin Microbiol 2007 45 : 1556 1560. Epub 2007 Feb 28.
39. Pendle S, Jelfs P, Olma T, Su Y, Gilroy N, Gilbert GL. Difficulties in detection and identification of Enterococcus faecium with low-level inducible resistance to vancomycin, during a hospital outbreak. Clin Microbiol Infect 2008 14 : 853 857.
40. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000 342 : 710 721.
41. Sandoe JA, Witherden IR, Au-Yeung HK, Kite P, Kerr KG, Wilcox MH. Enterococcal intravascular catheter-related bloodstream infection: Management and outcome of 61 consecutive cases. J Antimicrob Chemother 2002 50 : 577 582.
42. Howe RA, Robson M, Oakhill A, Cornish JM, Millar MR. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant Enterococcus. J Antimicrob Chemother 1997 40 : 144 145.
43. Perri MB, Hershberger E, Ionescu M, Lauter C, Zervos MJ. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002 42 : 269 271.
44. Shrestha NK, Chua JD, Tuohy MJ et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: Potential utility of fosfomycin. Scand J Infect Dis 2003 35 : 12 14.
45. Lautenbach E, Gould CV, LaRosa LA et al. Emergence of resistance to chloramphenicol among vancomycin-resistant enterococcal (VRE) bloodstream isolates. Int J Antimicrob Agents 2004 23 : 200 203. (Pubitemid 38175403)
46. Ricaurte JC, Boucher HW, Turett GS, Moellering RC, Labombardi VJ, Kislak JW. Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia. Clin Microbiol Infect 2001 7 : 17 21.
47. Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002 46 : 1845 1850.
48. Moellering RC. Quinupristin/dalfopristin: Therapeutic potential for vancomycin-resistant enterococcal infections. J Antimicrob Chemother 1999 44 (Suppl A 25 30.
49. Dowzicky M, Talbot GH, Feger C, Prokocimer P, Etienne J, Leclercq R. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis 2000 37 : 57 62.
50. Furlong WB, Rakowski TA. Therapy with RP 59500 (quinupristin/ dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns. Clin Infect Dis 1997 25 : 163 164.
51. Matsumura SO, Louie L, Louie M, Simor AE. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents. Antimicrob Agents Chemother 1999 43 : 2776 2779.
52. Safdar A, Bryan CS, Stinson S, Saunders DE. Prosthetic valve endocarditis due to vancomycin-resistant Enterococcus faecium: Treatment with chloramphenicol plus minocycline. Clin Infect Dis 2002 34 : E61 E63. Epub 2002 May 9.
53. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001 32 : 1373 1375. Epub 2001 Apr 9.
54. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999 44 : 251 261.
55. Winston DJ, Emmanouilides C, Kroeber A et al. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2000 30 : 790 797. Epub 2000 May 18.
56. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001 32 : e83 e86.
57. Carver PL, Whang E, VandenBussche HL, Kauffman CA, Malani PN. Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. Pharmacotherapy 2003 23 : 159 164.
58. Verma A, Dhawan A, Philpott-Howard J et al. Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: Safety and clinical efficacy of quinupristin/dalfopristin. J Antimicrob Chemother 2001 47 : 105 108.
59. McNeil SA, Clark NM, Chandrasekar PH, Kauffman CA. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin). Clin Infect Dis 2000 30 : 403 404.
60. Muñoz P, Rodríguez-Creixéms M, Moreno M, Marín M, Ramallo V, Bouza E GAME Study Group. Linezolid therapy for infective endocarditis. Clin Microbiol Infect 2007 13 : 211 215.
61. El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: Report of a multicenter compassionate-use trial. Transpl Infect Dis 2003 5 : 121 125.
62. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001 357 : 1179.
63. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002 346 : 867 869.
64. Rahim S, Pillai SK, Gold HS, Venkataraman L, Inglima K, Press RA. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003 36 : E146 E148. Epub 2003 May 20.
65. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004 53 : 530 532. Epub 2004 Feb 12.
66. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004 26 : 704 714.
67. Gavalda J, Len O, Miro JM et al. Brief communication: Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007 146 : 574 579.
68. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008 52 : 2403 2406. Epub 2008 Apr 28.
69. Bhalla A, Pultz NJ, Ray AJ, Hoyen CK, Eckstein EC, Donskey CJ. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol 2003 24 : 644 649.
70. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis 2000 181 : 1830 1833. Epub 2000 May 15.
71. Donskey CJ, Helfand MS, Pultz NJ, Rice LB. Effect of parenteral fluoroquinolone administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. Antimicrob Agents Chemother 2004 48 : 326 328.
72. Salgado CD. The risk of developing a vancomycin-resistant Enterococcus bloodstream infection for colonized patients. Am J Infect Control 2008 36 : S175 e5 e8.
73. Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007 35 (10 Suppl 2 S165 S193.
74. Martinez JA, Ruthazer R, Hansjosten K, Barefoot L, Snydman DR. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003 163 : 1905 1912.
75. Donskey CJ, Hoyen CK, Das SM, Helfand MS, Hecker MT. Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy. Infect Control Hosp Epidemiol 2002 23 : 436 440.
76. Hayden MK, Blom DW, Lyle EA, Moore CG, Weinstein RA. Risk of hand or glove contamination after contact with patients colonized with vancomycin-resistant Enterococcus or the colonized patients' environment. Infect Control Hosp Epidemiol 2008 29 : 149 154.
77. Vernon MO, Hayden MK, Trick WE, Hayes RA, Blom DW, Weinstein RA. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: The effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006 166 : 306 312.
78. Price CS, Paule S, Noskin GA, Peterson LR. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 2003 37 : 921 928. Epub 2003 Sep 12.
79. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003 24 : 362 386.
80. de Bruin MA, Riley LW. Does vancomycin prescribing intervention affect vancomycin-resistant Enterococcus infection and colonization in hospitals? A systematic review. BMC Infect Dis 2007 7 : 24.